A Comparative Study of Combined Adductor Canal and Interspace Between Popliteal Artery and Knee Capsule Versus Combined Adductor Canal and Genicular Nerve in Total Knee Arthroplasty

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorAin Shams University

About this trial

The aim of this study is to investigate the effectiveness of combined adductor canal block (ACB) with interspace between popliteal artery and the knee capsule (IPACK) versus combined ACB with genicular nerve block (GNB) for providing analgesia in knee arthroplasty. The investigators hypothesize that the analgesic efficacy of ACB combined with GNB will be non-inferior to that of ACB combined with IPACK. Additionally, the investigators aim to assess whether the combination of ACB and GNB results in a significantly lower occurrence of sensory or motor block affecting the tibial and common peroneal nerves compared to ACB and IPACK

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients American Society of anesthesiologists' physical status (ASA) I to III.

Aged 18 to 70 years.

Both sexes.

Patients scheduled for total knee arthroplasty.

Disqualifiers

Patient refusal

ASA physical status IV or more.

Patients with known allergy to any of the study drugs.

Infection at the site of injection.

Trial design

Design model

Parallel

Treatments tested in this trial

  • nerve block with bupivacaine 0.25%

    Drug

    ultrasound guided adductor canal block and interspace between the popliteal artery and the knee capsule using bupivacaine 0.25%

  • Nerve Block with bupivacaine 0.25%

    Drug

    ultrasound guided combined adductor canal block and genicular nerve block using bupivacaine 0.25%

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Patients receiving combined ACB and IPACK blocksActive comparator 1 intervention
Group B: Patients receiving combined ACB and GNBActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

individual visual analog pain scores at 0, 6, 12 , 24 and 48 h postoperatively

(VAS; 0 = no pain and 10 = worst pain imaginable)

Time frame
48 hours

Secondary outcomes

1

time to first reported pain and first analgesic request during post-anesthesia care unit stay

reported time in minutes

Time frame
48 hours
2

Analgesic consumption during the first 48 h post-surgery

Converted to IV pethidine equivalents. The analgesic dose of pethidine will be 0.5 mg/kg/dose to be repeated on demand

Time frame
48 hours
3

Quadriceps muscle strength

will be measured using the Straight Leg Raise (SLR) test, which will be conducted preoperatively and again 24 hours postoperatively. The SLR will be scored on a scale from 0 to 5, where 0 indicates no voluntary contraction, 1 signifies muscle flicker without limb movement, 2 represents active movement with gravity eliminated, 3 indicates movement against gravity but without resistance, 4 denotes movement against some resistance, and 5 reflects normal motor strength against resistance.

Time frame
24 hours
4

The sensorimotor functions of the tibial nerve and common peroneal nerve (CPN) will be evaluated using a 3-point scale

For sensory function, the scale will be as follows: 0 indicates normal sensation, 1 signifies lack of cold perception but intact touch sensation, and 2 denotes absence of touch sensation. For motor function, the scale will be: 0 for normal motor function, 1 for deficient motor function, and 2 for no motor function.

Time frame
8 hours postoperative

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: